Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-27

FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

View source ↗

Summary

The FDA approved a supplemental application for Kepivance (palifermin) from Swedish Orphan Biovitrum AB (publ). This action updates the product labeling accordi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kepivance (Palifermin)

Snippet

SUPPL AP for KEPIVANCE (PALIFERMIN)